Subscribe to RSS
Download PDF
DOI: 10.1055/a-2016-8392
Insulin Secretion Capacity as a Crucial Feature to Distinguish Type 1 From Type 2 Diabetes and to Indicate the Need for Insulin Therapy – A Critical Discussion of the ADA/EASD Consensus Statement on the Management of Type 1 Diabetes in Adults
Abstract
In the recently published consensus statement on the treatment and management of type 1 diabetes issued by experts from the American (ADA) and European (EASD) diabetes societies, measurement of endogenous insulin secretion using fasting C-peptide is recommended as a diagnostic criterion. In contrast, our group recently suggested fasting C-peptide/glucose ratio (CGR) for the determination of endogenous insulin secretion. In addition, this ratio may turn out as a potential decision aid for pathophysiologically based differential therapy of diabetes. In this comment, the following points will be discussed: i) CGR as the basis of differential diagnosis of type 1 diabetes, ii) CGR as the basis of treatment decisions for or against insulin in diabetes, and iii) the ease of application of CGR in clinical practice. The use of CGR may complement the ADA/EASD recommendations and should provide a practical application in clinical practice.
Publication History
Received: 13 June 2022
Received: 19 November 2022
Accepted: 23 December 2022
Article published online:
12 June 2023
© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1
American Diabetes Association.
Professional Practice Committee. Classification and diagnosis of diabetes:
Standards of medical care in diabetes-2022. Diabetes Care 2022; 45: S17-S38
MissingFormLabel
- 2 Holt RIG, DeVries JH, Hess-Fischl A. et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2021; 64: 2609-2652
- 3 Ahlqvist E, Storm P, Käräjämäki A. et al. Novel subgroups of adult-onset diabetes and their association with outcomes: A data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 2018; 6: 361-369
- 4 Wagner R, Heni M, Tabák AG. et al. Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes. Nat Med 2021; 27: 49-57
- 5
Fritsche A,
Heni M,
Peter A.
et al.
Considering insulin secretory capacity as measured by a fasting
C-peptide/glucose ratio in selecting glucose-lowering medications. Exp Clin Endocrinol
Diabetes 2022; 130: 200-204
MissingFormLabel
- 6 Thomas NJ, Jones SE, Weedon MN. et al. Frequency and phenotype of type 1 diabetes in the first six decades of life: A cross-sectional, genetically stratified survival analysis from UK Biobank. Lancet Diabetes Endocrinol 2018; 6: 122-129
- 7 Iwata M, Matsushita Y, Fukuda K. et al. Secretory units of islets in transplantation index is a useful predictor of insulin requirement in Japanese type 2 diabetic patients. J Diabetes Investig 2014; 5: 570-580
- 8 Herder C, Roden M. A novel diabetes typology: Towards precision diabetology from pathogenesis to treatment. Diabetologia 2022; 65: 1770-1781
- 9 Chung WK, Erion K, Florez JC. et al. Precision medicine in diabetes: A consensus report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2020; 43: 1617-1635
- 10 Hörber S, Orth M, Fritsche A, Peter A. Comparability of C-Peptide Measurements – Current Status and Clinical Relevance. Exp Clin Endocrinol Diabetes 2023; 131: 173–178